About Adicet Bio
Adicet Bio (NASDAQ:ACET) is a biotechnology company focused on the development and commercialization of cutting-edge cell therapies for cancer and other diseases. Trading exclusively on the NASDAQ with the symbol ACET, this firm is dedicated to innovating within the field of immuno-oncology, leveraging its expertise in gamma delta T cells to create novel treatments aimed at improving patient outcomes. Its projects include a diverse pipeline of proprietary allogeneic gamma delta T cell candidates designed to harness the innate and adaptive immune system. The objective of Adicet Bio is not only to advance its leading candidates through clinical trials but also to redefine the landscape of cell therapies, making significant strides in the fight against cancer.
Snapshot
Operations
Produtos e/ou serviços de Adicet Bio
- Developing 'gamma delta T cell' therapies targeting hematologic and solid tumors, highlighting its innovative cancer treatment approach.
- Advancement of ADI-001, aiming for B-cell non-Hodgkin's lymphoma, showcasing targeted cell therapy capabilities.
- Exploration of ADI-002 for solid tumors, emphasizing the versatility in treating various cancer types.
- Research on 'off-the-shelf' allogeneic gamma delta T cell products, offering potential for scalable cancer treatment options.
- Investment in gamma delta T receptor platform technology, underpinning the company's innovative therapeutic development.
- Collaboration with leading pharmaceutical companies to enhance research and development efforts in cancer therapy.
equipe executiva do Adicet Bio
- Mr. Chen Schor BA, CPA, M.B.A.CEO, President & Director
- Mr. Brian Nicholas HarveyChief Financial Officer
- Dr. Blake Aftab Ph.D.Senior VP & Chief Scientific Officer
- Dr. Donald Healey Ph.D.Chief Technology Officer
- Ms. Amy LockeChief Human Resource Officer
- Dr. Julie Maltzman M.D.Chief Medical Officer